Exelixis, Inc. (EXEL) EVP Jeffrey Hessekiel Sells 14,818 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 14,818 shares of the firm’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $19.25, for a total value of $285,246.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jeffrey Hessekiel also recently made the following trade(s):

  • On Wednesday, November 28th, Jeffrey Hessekiel sold 11,759 shares of Exelixis stock. The stock was sold at an average price of $19.12, for a total value of $224,832.08.

Shares of NASDAQ EXEL traded up $0.65 during midday trading on Friday, reaching $20.31. 3,573,829 shares of the company were exchanged, compared to its average volume of 4,446,562. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01. Exelixis, Inc. has a 1 year low of $13.42 and a 1 year high of $32.20. The firm has a market cap of $5.88 billion, a P/E ratio of 39.82, a P/E/G ratio of 1.17 and a beta of 2.29.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The firm had revenue of $225.40 million for the quarter, compared to analyst estimates of $174.14 million. During the same quarter last year, the company posted $0.26 earnings per share. The business’s revenue was up 47.8% on a year-over-year basis. As a group, analysts anticipate that Exelixis, Inc. will post 1.3 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Exelixis by 16.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,599 shares of the biotechnology company’s stock worth $443,000 after buying an additional 2,948 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Exelixis by 17.1% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 23,496 shares of the biotechnology company’s stock worth $416,000 after buying an additional 3,428 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Exelixis by 31.2% during the second quarter. Janney Montgomery Scott LLC now owns 17,220 shares of the biotechnology company’s stock worth $371,000 after buying an additional 4,095 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Exelixis by 21.2% during the third quarter. Meeder Asset Management Inc. now owns 23,504 shares of the biotechnology company’s stock worth $416,000 after buying an additional 4,117 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Exelixis by 5.1% during the first quarter. Principal Financial Group Inc. now owns 91,006 shares of the biotechnology company’s stock worth $2,016,000 after buying an additional 4,445 shares during the last quarter. 79.37% of the stock is currently owned by hedge funds and other institutional investors.

EXEL has been the topic of several research reports. Guggenheim initiated coverage on Exelixis in a report on Monday, September 17th. They set a “buy” rating on the stock. Goldman Sachs Group initiated coverage on Exelixis in a report on Monday, September 17th. They set a “neutral” rating and a $22.00 price objective on the stock. Morgan Stanley initiated coverage on Exelixis in a report on Monday, September 10th. They set an “underweight” rating and a $19.00 price objective on the stock. BidaskClub raised Exelixis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 30th. Finally, Oppenheimer set a $40.00 price objective on Exelixis and gave the stock a “buy” rating in a report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $29.44.

TRADEMARK VIOLATION NOTICE: This news story was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/12/01/exelixis-inc-exel-evp-jeffrey-hessekiel-sells-14818-shares-of-stock.html.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Further Reading: Risk Tolerance and Your Investment Decisions

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply